Despite challenges of decision making for unrepresented patients, few laws or policy statements offer solutions. This article offers 5 key things to do.
AMA J Ethics. 2019;21(7):E582-586. doi:
10.1001/amajethics.2019.582.
Carmel Shachar, JD, MPH and Dorit Rubinstein Reiss, LLB, PhD
Legal approaches to preserving social stability, maintaining trust, supporting therapeutic research opportunities, or diminishing disease severity deserve ethical scrutiny.
AMA J Ethics. 2020;22(1):E36-42. doi:
10.1001/amajethics.2020.36.